Leyens Lada, Horgan Denis, Lal Jonathan A, Steinhausen Kirsten, Satyamoorthy Kapaettu, Brand Angela
Institute for Public Health Genomics, Department of Genetics & Cell Biology, School for Oncology & Developmental Biology (GROW), Faculty of Health Medicine & Life Sciences, Maastricht University, Maastricht, The Netherlands.
European Alliance for Personalized Medicine, Brussels, Belgium.
Per Med. 2014 Sep;11(7):641-649. doi: 10.2217/pme.14.55.
Rapid advances in 'omics' sciences and technologies have elevated the relevance of personalized medicine. This article reviews the current advances in the application of personalized medicine, outlines and summarizes the key areas that still need to be addressed and gives recommendations in this direction. Eighteen relevant high-level reports on personalized medicine were reviewed in order to identify the gaps and needs that are present for the implementation of personalized medicine. We identify 12 key areas that represent the main obstacles on the road towards the personalization of medicine and divide these 12 key areas into four domains, namely: scientific research and stakeholder collaboration; translational tools; regulations and systematic early dialog with regulators; and uptake into healthcare systems. All of the evaluated reports agree on the imperative need for intensive collaboration among all stakeholders with early active participation and changes in the current healthcare infrastructure.
“组学”科学与技术的飞速发展提升了个性化医疗的重要性。本文回顾了个性化医疗应用的当前进展，概述并总结了仍需解决的关键领域，并在此方向上给出了建议。为了确定实施个性化医疗存在的差距和需求，对18份关于个性化医疗的相关高级别报告进行了审查。我们确定了12个关键领域，它们是实现医疗个性化道路上的主要障碍，并将这12个关键领域分为四个领域，即：科研与利益相关者合作；转化工具；法规以及与监管机构的系统性早期对话；以及纳入医疗保健系统。所有评估报告都一致认为，所有利益相关者必须进行深入合作，早期积极参与，并改变当前的医疗基础设施。
